Authors:Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group on behalf of the Ontario COVID-19 Science Advisory Table and University of Waterloo School of Pharmacy
This version is outdated. Please see https://doi.org/10.47326/ocsat.2022.03.58.1.0 for the latest version of the Nirmatrelvir/Ritonavir (Paxlovid): What Prescribers and Pharmacists Need to Know.
For the most up-to date information, please visit Paxlovid Prescribing & Drug Interaction Information from the Immunodeficiency Clinic at University Health Network.
Citation: Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group, University of Waterloo School of Pharmacy. Nirmatrelvir/Ritonavir (Paxlovid): What prescribers and pharmacists need to know. Ontario COVID-19 Science Advisory Table. 2022;3(58). https://doi.org/10.47326/ocsat.2022.03.58.3.0
Author Affiliations: The affiliations of the members of the Ontario COVID-19 Science Advisory Table and the Drugs & Biologics Clinical Practice Guidelines Working Group can be found at https://covid19-sciencetable.ca/about.
Declarations of Interest: The declarations of interest of the members of the Ontario COVID-19 Science Advisory Table and the Drugs & Biologics Clinical Practice Guidelines Working Group can be found at https://covid19-sciencetable.ca/about.
Copyright: 2022 Ontario COVID-19 Science Advisory Table. This is an open access document distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
